This systematic review aims to assess the rates and types of adverse events associated with CPX‐351 compared to conventional induction chemotherapy regimens, evaluate its effectiveness in terms of remission rates and survival outcomes, and examine its potential role in improving treatment outcomes for high‐risk AML patients, including those with t‐AML and AML‐MRC [16, 17, 18, 19, 20]. This evidence concerns the gene CD200 and acute myeloid leukemia.